


BTG 1640

Cat. No.:	HY-106439
CAS No.:	152538-59-5
Molecular Formula:	C ₁₅ H ₁₉ NO ₂
Molecular Weight:	245.32
Target:	Chloride Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BTG 1640 (ABIO-08/01) is a potent anxiolytic isoxazoline. BTG 1640 is a selective inhibitor of GABA- and glutamate-gated chloride channels ^[1] .
IC₅₀ & Target	GABA- and glutamate-gated chloride channels ^[1]
In Vivo	BTG 1640 (ABIO-08/01) displays an activity at a very low dosage after single intraperitoneal and single oral administration (gavage) in mouse and rat models of anxiety. Chronic administration resulted neither in tolerance development nor in withdrawal symptoms after abrupt discontinuation of treatment (data on file) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Correll CU, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. *World Psychiatry*. 2023 Feb;22(1):48-74.

[2]. Saletu-Zyhlarz GM, et al. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings. *Neuropsychobiology*. 2009;59(2):100-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA